Research Article
The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients
Table 2
Comparison between the two studied markers SOX2 and AGR2 with Her2neu and ki67 expression in the three studied groups.
| | | Group 1 (n = 124) | Group 2 (n = 48) | Group 3 (n = 52) | Test of sig. | |
| | SOX2 | | | | | | | Negative | 42 (33.9%) | 0 (0.0%) | 0 (0.0%) | X2 = 41.687 | <0.001 | | Positive | 82 (66.1%) | 48 (100.0%) | 52 (100.0%) | | SOX2 score | | | | | | | Negative | 42 (33.9%) | 0 (0.0%) | 0 (0.0%) | X2 = 191.275 | <0.001 | | Low | 82 (66.1%) | 5 (10.4%) | 4 (7.7%) | | High | 0 (0.0%) | 43 (89.6%) | 48 (92.3%) | | AGR2 | | | | | | | Negative | 39 (31.5%) | 0 (0.0%) | 0 (0.0%) | X2 = 38.082 | <0.001 | | Positive | 85 (68.5%) | 48 (100.0%) | 52 (100.0%) | | AGR2score | | | | | | | Negative | 39 (31.5%) | 0 (0.0%) | 0 (0.0%) | X2 = 225.905 | <0.001 | | Low | 85 (68.5%) | 5 (10.4%) | 6 (11.5%) | | High | 0 (0.0%) | 43 (89.6%) | 46 (88.5%) | | Serum AGR2 level | | | | | | | Mean ± SD. | 12 ± 9.1 | 141 ± 55.2 | 156.8 ± 44.7 | H = 152.495 | <0.001 | | Median (min. – Max.) | 7 (2–32) | 130 (4–228) | 159.5(9–236) | | Her2neu | | | | | | | Negative | 87 (70.2%) | 31 (64.6%) | 31 (59.6%) | X2 = 1.932 | 0.381 | | Positive | 37 (29.8%) | 17 (35.4%) | 21 (40.4%) | | Her2neu score | | | | | | | 0 | 43 (34.7%) | 15 (31.3%) | 14 (26.9%) | X2 = 2.105 | 0.910 | | +1 | 44 (35.5%) | 16 (33.3%) | 17 (32.7%) | | +2 | 20 (16.1%) | 9 (18.8%) | 11 (21.2%) | | +3 | 17 (13.7%) | 8 (16.7%) | 10 (19.2%) | | Ki67 index | | | | | | | Mean ± SD. | 16.1 ± 9.7 | 14.7 ± 9.4 | 17.8 ± 10 | H = 2.432 | 0.296 | | Median (min. – Max.) | 15 (3.8–40) | 13 (4–38) | 16.5 (3.8–40) |
|
|
χ2: Chi square test, H: H for Kruskal–Wallis test. Statistically significant at . |
